Themis Medicare Ltd.
Snapshot View

930.00 +5.55 ▲0.6%

05 August 2021, 04:00:00 P.M.
Volume: 1,375

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.themismedicare.com
Financial Indicators
Market Cap 849.94 Cr.
Earnings per share (EPS) 38.83 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 23.81 Trailing Twelve Months Ending 2021-03
Industry PE 32.74 Trailing Twelve Months Ending 2021-03
Book Value / Share 200.07 Trailing Twelve Months Ending 2021-03
Price to Book Value 4.62 Calculated using Price: 924.45
Dividend Yield 0.19 Period Ending 2020-03
No. of Shares Subscribed 0.92 Cr. 9,193,962 Shares
FaceValue 10
Company Profile

Themis Medicare (TML) incorporated in 1969, is engaged in manufacturing of Active Pharmaceutical Ingredients (APIs) and Formulations. Erstwhile known as Themis Chemical the company is promoted by Mr. Shantibhai D. Patel. It is joint venture with Gedeon Richter, Hungary.

Headquartered in Mumbai, the company has four manufacturing facilities located at Vapi (Gujarat), Hyderabad (Andhra Pradesh), and Haridwar (Uttaranchal).

The company is backed by strong marketing workforce of 500 people with network of over 2000 stockists. The company has pan-India presence; it also has presence in 40 countries that include international markets namely Europe, Americas and Australasia.

Company has an in-house R&D facility that focuses on development of new chemical, new and efficient processes for production of API and intermediates, fermentation technology and New Drug Delivery Systems.

Themis Medicare is also engaged in supplying its research formulations to well known Pharmaceutical companies in India namely Alkem Lab, Fulford, Intas Pharmaceuticals, IPCA Lab., Cadila Healthcare, Aristo Pharma, Mankind Pharma, Shreya Lifesciences, Nicholas Piramal, Unichem Lab, etc.

Products

Active Pharmaceutical Ingredients- The Company is manufactures APIs that caters to therapeutic segment such as antituberculosis, antimalarials, cardiology, pain management, anti-infectives, haematinics, health and nutrition. Company manufactures products namely Simvastatin, Lovastatin, Propofol, Ethambutol, Di-methyl Isosorbide, Artesunate, Lumefenterine, Arteether are among others.

Formulations- The company also formulations that caters to therapeutic segment. It has produced products such as Themibutol, Tetracox, Tricox, Ticinex, Ticin are among others.

Milestones

1969- Themis Chemicals was incorporated in joint venture with GEDEON Richter, Hungary.

1971- Themis Chemicals became first company in India and second company in the world to manufacture Vitamin B12 by non-sterile fermentation process.

1976- Themis Chemicals became first company in India and second company in the world to manufacture Ethambutol Dihydrochloride.

1985- RIFAMPICIN was produced for first time in India by Themis Chemicals.

1990- Company developed and manufactured HEMOLOK.

1991-92 Besides Schering Plough of USA, company was only one to manufactures SISOMICIN. Company developed and manufactured ANABLOKTM – an anaesthetic.

1993- It was only private sector company to produce GENTAMICIN in India

1995- For the first time in the world the company produces FUMAGILLIN– a unique veterinary productThemis Chemicals is listed on the Bombay Stock Exchange.

1996- The company became first in India and third in the world to produce LOVASTATIN.

1997- Company received award from Ministry of Science and Technology’s Department of Scientific and Industrial Research (DSIR).

1998- Company developed Simvastatin for the first time in Asia.

1999- Company launched E MALTM – Alpha Beta Arteether and it also received award from Ministry of Science and Technology’s Department of Scientific and Industrial Research (DSIR) for the same.

2001- Company was rechristened as Themis Medicare

2002- The company for first time in India developed SEPGARDTM – a unique wound healing agent.

2003- For first time in the world, company developed CLEOFOLTM- a Lipid free Clear Propofol Injection. In the same year it also introduced the first COX-2 INJECTION in the world.

2004- Artemis Biotech was merged with Themis Medicare. The company forms its second joint venture with Gedeon Richter of Hungary to set up 100% export oriented unit under the name Richter Themis Medicare (INDIA). The same year the company commissions a new facility at Hyderabad.

2006- Company starts operations of its manufacturing unit located at Haridwar. Company develops and introduces Nimesulide Injection. Company launches THEMISEALTM- a stops bleeding gel and forays in European market. Company started cultivation of Artemisia annua and extraction of Artemisinin.

2007- For first time in the world, the company introduced Aceclofenac Injection.

2010 - Themis Medicare launched a combination of Lidocaine & Prilocaine in 'Spray' form under the brand name ""Lovelong""
2011 - Themis Medicare have introduced for the First Time in the Country a 'calcium' preparation with fruitygummies for paediatric use under the brand name "THEMIBEAR".
The Company have introduced for the First Time in the country a ""Multivitamin"" for Paediatric use under the brand name "THEMIBEAR"
2013 - Introduction of oil free Emal (Alpha beta arteether injection) in ampoules, and PFS  (Pre-Filled Syringe)
Break through development of Diclofenac 75 mg / ml injection using patented technology and assigned exclusive marketing rights to Novartis India Limited under their flagship brand - Voveran 75 mg / ml Injection
Long term partnership signed with Novartis India Limited for exclusive marketing rights of Diclofenac TPM Gel (Voveran TPM Gel) for India

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+0.60%
1 Week
-0.02%
1 Month
+27.86%
3 Month
+143.65%
6 Month
+179.66%
1 Year
+136.22%
2 Year
+506.06%
5 Year
+81.27%
9 years 2012-03 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) -43.27 -11.50 5.00 9.40 22.85 13.16 5.42 -8.00 9.34
Return on Capital Employed (%) -8.28 5.39 9.53 9.45 14.69 12.92 8.52 -1.25 11.81
Return on Assets (%) -11.32 -2.29 0.97 1.94 5.52 5.29 2.95 -4.29 4.86

Balance Sheet View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 59 52 57 59 74 152 169 158 183
Non Curr. Liab. 72 99 90 82 71 8 7 3 8
Curr. Liab. 150 120 137 136 130 124 125 147 155
Minority Int. 0 0
Equity & Liab. 280 272 284 277 275 284 301 307 345
Non Curr. Assets 151 148 149 143 142 160 157 158 165
Curr. Assets 129 124 134 133 133 124 143 150 180
Misc. Exp. not W/O
Total Assets 280 272 284 277 275 284 301 307 345

Profit Loss View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 158 174 195 202 232 217 210 184 202
Other Income 3 3 5 13 3 3 3 3 3
Total Income 161 177 200 214 236 220 213 186 205
Total Expenditure -171 -157 -171 -184 -194 -184 -185 -181 -166
PBIDT -10 20 29 31 41 36 28 5 39
Interest -14 -15 -16 -15 -12 -12 -12 -12 -13
Depreciation -8 -9 -9 -11 -12 -7 -7 -8 -8
Taxation -1 -2 -1 1 -2 -2 0 2 -2
Exceptional Items
PAT -32 -6 3 5 15 15 9 -13 16

Cash Flow View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. -14 4 8 19 26 -2 8 11 0
Cash Fr. Inv. -12 -5 -7 -6 -7 -4 0 -4 -5
Cash Fr. Finan. 5 29 2 -18 -13 5 -9 -10 7
Net Change -21 29 4 -5 5 0 -1 -3 2
Cash & Cash Eqvt -67 -38 -35 -40 -34 6 4 2 3

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 67.32 67.32 67.32 67.27 67.27 67.27 67.26 67.26 67.22
Public 32.68 32.68 32.68 32.73 32.73 32.73 32.74 32.74 32.78
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Wed, 04 Aug 2021
Board Meeting Intimation for Intimation Of Date Of Board Meeting & Closure Of Trading Window
THEMIS MEDICARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2021 inter alia to consider and approve Please be informed that a meeting of the Board of Directors of Themis Medicare Limited is scheduled to be held on Friday 13th August 2021 inter alia to consider the Un-audited Standalone and Consolidated Financial Results for the Quarter ended on 30th June 2021.

Further in continuation of our Letter dated 30th June 2021 the Trading Window in respect of dealing in the Companys Securities was closed for all Directors/Designated Employees from the opening of the trading hours on Thursday 1st July 2021 and shall remain closed till the closure of trading hours on 15th August 2021 (both days inclusive) i.e. till the completion of 48 hours after the declaration of financial results as per the policy for prohibition of Insider Trading ("the Code") adopted by the Company pursuant to SEBI (Prohibition of Insider Trading) Regulations 2015 as amended from time to time.

This is for your information and record.
Fri, 16 Jul 2021
Shareholding for the Period Ended June 30 2021
Themis Medicare Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30 2021. For more details kindly Click here
Mon, 12 Jul 2021
Statement Of Investor Complaints For The Quarter Ended June 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter
0110
Name of the Signatory :- Sangameshwar Iyer
Designation :- Company Secretary and Compliance Officer

Technical Scans View Details

Wed, 04 Aug 2021
Close Crossing Last Month Close from Above Close Crossing Last Month Close from Above
Close Within 52 Week High Zone Close Within 52 Week High Zone
Increasing Relative Strength - Sectoral Index Increasing Relative Strength - Sectoral Index
MFI Trending Down MFI Trending Down
Tue, 03 Aug 2021
Making Higher Highs for 3 days Making Higher Highs for 3 days

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 188,527.75 785.85 +0.0%
Divi's Laboratories Ltd. 131,785.24 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. 79,333.82 4,783.30 +0.2%
Cipla Ltd. 75,796.16 945.20 +0.6%
Cadila Healthcare Ltd. 60,170.47 584.80 -0.5%
Apollo Hospitals Enterprise Ltd. 58,468.59 4,075.50 +0.2%
Piramal Enterprises Ltd. 57,915.28 2,601.15 +2.0%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-06 31.40 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2021-03 66.41 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 45.66 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 31.52 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 28.20 584.80 -0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 388.86 4,075.50 +0.2%
Piramal Enterprises Ltd. Consolidated 2021-03 43.47 2,601.15 +2.0%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-06 3.94 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2021-03 14.18 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 4.44 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 4.15 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 4.63 584.80 -0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.72 4,075.50 +0.2%
Piramal Enterprises Ltd. Consolidated 2021-03 1.69 2,601.15 +2.0%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 0.10 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 584.80 -0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,075.50 +0.2%
Piramal Enterprises Ltd. Consolidated 2021-03 1.16 2,601.15 +2.0%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 14.13 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 584.80 -0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,075.50 +0.2%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 2,601.15 +2.0%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 17.85 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 584.80 -0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,075.50 +0.2%
Piramal Enterprises Ltd. Consolidated 2021-03 10.03 2,601.15 +2.0%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2020-03 6,969.40 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 19,159.59 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 584.80 -0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,075.50 +0.2%
Piramal Enterprises Ltd. Consolidated 2021-03 12,809.35 2,601.15 +2.0%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2020-03 1,984.29 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 2,401.30 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 584.80 -0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,075.50 +0.2%
Piramal Enterprises Ltd. Consolidated 2021-03 1,074.43 2,601.15 +2.0%